keyword
MENU ▼
Read by QxMD icon Read
search

Allogeneic transplantation

keyword
https://www.readbyqxmd.com/read/29475213/modified-multivisceral-transplantation-with-native-spleen-removal-in-rats
#1
Pablo Stringa, Nidia Monserrat Arreola, Ane M Andres Moreno, Carlota Largo, Martín Rumbo, Francisco Hernandez
BACKGROUND:  Modified multivisceral transplantation (MMVTx) refers to the use of a graft that includes all abdominal organs except the liver. The use of this type of transplant in children and adults expanded over the last years with good results. However, long-term survival in experimental models has not been reported. Our aim is to describe in detail some technical modifications of MMVTx to obtain long-term survival. MATERIALS AND METHODS:  Syngeneic (Lewis-Lewis) heterotopic MMVTx was performed in 16 male rats (180-250 g)...
February 23, 2018: European Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29474870/improving-revised-international-prognostic-scoring-system-ipss-r-pre-allogeneic-stem-cell-transplant-does-not-translate-into-better-post-transplant-outcomes-for-patients-with-myelodysplastic-syndromes-a-single-center-experience
#2
Musa Alzahrani, Maryse Power, Yasser Abou Mourad, Michael Barnett, Raewyn Broady, Donna Forrest, Alina Gerrie, Donna Hogge, Stephen Nantel, David Sanford, Kevin Song, Heather Sutherland, Cynthia Toze, Thomas Nevill, Sujaatha Narayanan
BACKGROUND: The natural history of patients with myelodysplastic syndromes (MDS) is variable. The revised international prognostic score (IPSS-R) is commonly used in practice to predict outcome in patients with MDS both at diagnosis and pre-transplant. However the effect of change in IPSS-R pre-allogeneic stem cell transplant with chemotherapy or hypomethylating agents on post-transplant outcomes is currently unknown. AIM: We assessed if improvement in IPSS-R prognostic score pre HSCT would result in improvement in clinical outcomes post-transplant...
February 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29474869/in-the-era-of-bcr-abl1-inhibitors-are-we-closing-the-survival-gap-between-allogeneic-hematopoietic-cell-transplantation-and-chemotherapy-for-ph-all-in-first-complete-remission
#3
EDITORIAL
Matthew J Wieduwilt
No abstract text is available yet for this article.
February 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29472928/immunothrombotic-activity-of-damage-associated-molecular-patterns-and-extracellular-vesicles-in-secondary-organ-failure-induced-by-trauma-and-sterile-insults
#4
REVIEW
John Eppensteiner, Robert Patrick Davis, Andrew S Barbas, Jean Kwun, Jaewoo Lee
Despite significant improvements in injury prevention and emergency response, injury-related death and morbidity continues to increase in the US and worldwide. Patients with trauma, invasive operations, anti-cancer treatment, and organ transplantation produce a host of danger signals and high levels of pro-inflammatory and pro-thrombotic mediators, such as damage-associated molecular patterns (DAMPs) and extracellular vesicles (EVs). DAMPs (e.g., nucleic acids, histone, high-mobility group box 1 protein, and S100) are molecules released from injured, stressed, or activated cells that act as endogenous ligands of innate immune receptors, whereas EVs (e...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29472724/persistence-of-pre-leukemic-clones-during-first-remission-and-risk-of-relapse-in-acute-myeloid-leukemia
#5
Maja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, Thomas Köhnke, Nikola P Konstandin, Stephanie Schneider, Maria C Sauerland, Tobias Herold, Max Hubmann, Bianka Ksienzyk, Evelyn Zellmeier, Stefan K Bohlander, Marion Subklewe, Andreas Faldum, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus H Metzeler
Some patients with acute myeloid leukemia (AML) who are in complete remission after induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-associated somatic mutations. There is conflicting evidence on the prognostic relevance of these clones for AML relapse. Here, we characterized paired pre-treatment and remission samples from 126 AML patients for mutations in 68 leukemia-associated genes. Fifty patients (40%) retained ≥1 mutation during remission at a VAF of ≥2%. Mutation persistence was most frequent in DNMT3A (65% of patients with mutations at diagnosis), SRSF2 (64%), TET2 (55%), and ASXL1 (46%), and significantly associated with older age (p < 0...
February 23, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29472720/car-t-cells-targeting-flt3-have-potent-activity-against-flt3-itd-aml-and-act-synergistically-with-the-flt3-inhibitor-crenolanib
#6
Hardikkumar Jetani, Irene Garcia-Cadenas, Thomas Nerreter, Simone Thomas, Julian Rydzek, Javier Briones Meijide, Halvard Bonig, Wolfgang Herr, Jordi Sierra, Hermann Einsele, Michael Hudecek
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer potent reactivity against AML cell lines and primary AML blasts that express either wild-type FLT3 or FLT3 with internal tandem duplication (FLT3-ITD). We also show that treatment with the FLT3-inhibitor crenolanib leads to increased surface expression of FLT3 specifically on FLT3-ITD+ AML cells and consecutively, enhanced recognition by FLT3-CAR T-cells in vitro and in vivo...
February 5, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29470425/major-histocompatibility-complex-and-hematopoietic-stem-cell-transplantation-beyond-the-classical-hla-polymorphism
#7
REVIEW
Alice Bertaina, Marco Andreani
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a curative treatment for many patients with hematological malignant or non-malignant disorders. Evaluation of potential donors for HSCT includes a rigorous assessment of the human leukocyte antigens (HLA) match status of family members, and the identification of suitable unrelated donors. Genes encoding transplantation antigens are placed both within and outside the major histocompatibility complex (MHC). The human MHC is located on the short arm of chromosome 6 and contains a series of genes encoding two distinct types of highly polymorphic cell surface glycoproteins...
February 22, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29469961/relapse-and-survival-after-transplantation-for-complex-karyotype-acute-myeloid-leukemia-a-report-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation-and-the-university-of-texas-md-anderson-cancer-center
#8
Stefan O Ciurea, Myriam Labopin, Gerard Socie, Liisa Volin, Jakob Passweg, Patrice Chevallier, Dietrich Beelen, Noel Milpied, Didier Blaise, Jan J Cornelissen, Nathalie Fegueux, Emmanuelle Polge, Piyanuch Kongtim, Gabriela Rondon, Jordi Esteve, Mohamad Mohty, Bipin N Savani, Richard E Champlin, Arnon Nagler
BACKGROUND: Despite recent advances in allogeneic hematopoietic stem cell transplantation (AHSCT), the outcome of patients who have acute myeloid leukemia (AML) with a complex karyotype (CK) remains poor. The objective of this study was to identify prognostic factors associated with post-transplantation survival in a large cohort of patients with CK AML. METHODS: In total, data on 1342 consecutively patients who underwent transplantation for CK (≥3 chromosomal abnormalities) AML were provided by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and from the University of Texas MD Anderson Cancer Center database were included in the analysis...
February 22, 2018: Cancer
https://www.readbyqxmd.com/read/29469783/delayed-presentation-of-toxic-epidermal-necrolysis-like-cutaneous-acute-graft-versus-host-disease-in-the-setting-of-recent-immunosuppressant-discontinuation
#9
Parul K Kathuria Goyal, Shuai Xu, Jennifer Choi
Acute graft-versus-host disease (GvHD) is a process that classically has been defined as occurring less than 100 days after stem cell transplant. When Stage IV cutaneous acute GvHD occurs outside this window, it can be difficult to distinguish clinically from toxic epidermal necrolysis (TEN). A 50-year-old man with diffuse large B-cell lymphoma who had undergone an allogeneic stem cell transplant 20 months previously was admitted for neutropenic septic shock. He developed a slowly progressing macular/papular eruption with multiple tender bullae found to be consistent with TEN-like Stage IV cutaneous acute GvHD on biopsy...
October 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29469718/eccrine-squamous-syringometaplasia-in-an-allogenic-stem-cell-transplant-patient-undergoing-chemotherapy
#10
Kevin Nethers, Jane Messina, Lucia Seminario-Vidal
Eccrine squamous syringometaplasia (ESS) is a rare finding defined as metaplastic change of the cuboidal epithelial cells of eccrine glands into two or more layers of squamous epithelial cells. We present a patient who developed ESS after induction of CLAG chemotherapy [2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and (granulocyte-colony stimulating factor) G-CSF] for management of the blast crisis of his chronic myelogenous leukemia (CML). Our patient's ESS eruption presented with a variety of morphologies, thus multiple skin biopsies were taken to determine the possible diagnosis(es)...
September 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29468647/brentuximab-vedotin-prior-to-allogeneic-stem-cell-transplantation-in-hodgkin-lymphoma-a-report-from-the-ebmt-lymphoma-working-party
#11
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Karl S Peggs, Didier Blaise, Boris Afanasyev, José L Diez-Martin, Jorge Sierra, Adrian Bloor, Carmen Martinez, Stephen Robinson, Ram Malladi, Jean El-Cheikh, Paolo Corradini, Silvia Montoto, Peter Dreger, Anna Sureda
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma (HL) when used as pre-transplant salvage therapy. Between 2010 and 2014, 428 adult patients underwent an allogeneic SCT for classical HL at participating centres of the European Society for Blood and Marrow Transplantation. We compared the outcomes of 210 patients who received BV prior to allogeneic SCT with that of 218 patients who did not receive BV...
February 22, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29468631/high-dose-melphalan-based-sequential-conditioning-chemotherapy-followed-by-allogeneic-haematopoietic-stem-cell-transplantation-in-adult-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia
#12
Nina K Steckel, Christoph Groth, Jan-Henrik Mikesch, Rudolf Trenschel, Hellmut Ottinger, Lambros Kordelas, Carsten Mueller-Tidow, Christoph Schliemann, Christian Reicherts, Joern C Albring, Gerda Silling, Eva Schmidt, Wolfgang E Berdel, Georg Lenz, Markus Ditschkowski, Dietrich W Beelen, Matthias Stelljes
Considering the unsatisfactory results of salvage therapies for patients with relapsed/refractory acute myeloid leukaemia (R/R-AML), their value before allogeneic haematopoietic stem cell transplantation (HSCT) remains questionable. However, direct allogeneic HSCT following established conditioning regimens applied in patients with R/R-AML during active disease has been equally disappointing. In this retrospective observational study, high-dose melphalan, as part of a sequential preparative regimen, followed by a total body irradiation (4 × 2 Gy)-based or a treosulfan-based dose-adapted conditioning therapy for allogeneic HSCT was administered to 292 adult patients (median age 56 years, range 17-74) with primary refractory (144 patients), secondary refractory (97 patients) or relapsed AML (51 patients)...
February 21, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29467322/gut-microbiota-modulates-adoptive-cell-therapy-via-cd8%C3%AE-dendritic-cells-and-il-12
#13
Mireia Uribe-Herranz, Kyle Bittinger, Stavros Rafail, Sonia Guedan, Stefano Pierini, Ceylan Tanes, Alex Ganetsky, Mark A Morgan, Saar Gill, Janos L Tanyi, Frederic D Bushman, Carl H June, Andrea Facciabene
Adoptive T cell therapy (ACT) is a promising new modality for malignancies. Here, we report that adoptive T cell efficacy in tumor-bearing mice is significantly affected by differences in the native composition of the gut microbiome or treatment with antibiotics, or by heterologous fecal transfer. Depletion of bacteria with vancomycin decreased the rate of tumor growth in mice from The Jackson Laboratory receiving ACT, whereas treatment with neomycin and metronidazole had no effect, indicating the role of specific bacteria in host response...
February 22, 2018: JCI Insight
https://www.readbyqxmd.com/read/29467192/combination-of-the-low-anticoagulant-heparin-cx-01-with-chemotherapy-for-the-treatment-of-acute-myeloid-leukemia
#14
Tibor J Kovacsovics, Alice Mims, Mohamed E Salama, Jeremy Pantin, Narayanam Rao, Ken M Kosak, Peter Ahorukomeye, Martha J Glenn, Michael W N Deininger, Kenneth M Boucher, Linda M Bavisotto, Gerardo Gutierrez-Sanchez, Thomas P Kennedy, Stephen G Marcus, Paul J Shami
Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women)...
February 27, 2018: Blood Advances
https://www.readbyqxmd.com/read/29466350/heart-rate-variability-markers-as-correlates-of-survival-in-recipients-of-hematopoietic-cell-transplantation
#15
Caroline Scheiber, Laura Johnston, Mary Packer, Richard Gevirtz, Katharine S Edwards, Oxana Palesh
OBJECTIVES: To assess pre-/post-transplantation changes in autonomic tone, as measured by heart rate variability (HRV), among patients undergoing hematopoietic cell transplantation (HCT) and to look at those changes as they relate to post-transplantation survival rates. 
. SAMPLE &AMP; SETTING: Data were derived from a sample of 27 English-speaking patients undergoing allogeneic or autologous HCT at Stanford University. 
. METHODS &AMP; VARIABLES: A survival analysis using the Kaplan-Meier estimator was employed to explore whether increased HRV would enhance survival probabilities over time among patients undergoing HCT...
March 1, 2018: Oncology Nursing Forum
https://www.readbyqxmd.com/read/29465425/optimization-of-nutrition-during-allogeneic-hematologic-stem-cell-transplantation
#16
Annic Baumgartner, Katja Hoskin, Philipp Schuetz
PURPOSE OF REVIEW: Malnutrition before and during hematopoietic stem cell transplantation (HSCT) is an independent risk factor for mortality in patients undergoing hematopoietic stem cell transplantation. Yet, optimal use of nutritional support to improve outcomes remains controversial. Our aim was to do an up-to-date literature review regarding nutritional therapy in allogeneic HSCT, the neutropenic diet and the use of immunonutrients. RECENT FINDINGS: Several observational studies find malnutrition to be associated with poor outcome, increased complications and lower overall survival...
February 19, 2018: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/29464765/delay-of-alternative-antiviral-therapy-and-poor-outcomes-of-acyclovir-resistant-herpes-simplex-virus-infections-in-recipients-of-allogeneic-stem-cell-transplant
#17
Ella J Ariza-Heredia, Roy F Chemaly, Lokesh R Shahani, Ying Jang, Richard Champlin, Victor E Mulanovich
Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyclovir-resistant HSV by plaque reduction test who received an HCT from 2002 through 2014. A total of 4028 HCTs were performed during the study period, and 18 of the recipients met the diagnostic criteria for acyclovir-resistant HSV...
February 21, 2018: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/29463563/first-in-human-phase-1-clinical-study-of-the-il-15-superagonist-complex-alt-803-to-treat-relapse-after-transplantation
#18
Rizwan Romee, Sarah Cooley, Melissa M Berrien-Elliott, Peter Westervelt, Michael R Verneris, John E Wagner, Daniel J Weisdorf, Bruce R Blazar, Celalettin Ustun, Todd E DeFor, Sithara Vivek, Lindsey Peck, John F DiPersio, Amanda F Cashen, Rachel Kyllo, Amy Musiek, András Schaffer, Milan J Anadkat, Ilana Rosman, Daniel Miller, Jack O Egan, Emily K Jeng, Amy Rock, Hing C Wong, Todd A Fehniger, Jeffrey S Miller
New therapies for patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) are needed. Interleukin (IL)-15 is a cytokine that stimulates CD8+ T cell and NK cell anti-tumor responses, and we hypothesized this cytokine may augment anti-leukemia/lymphoma immunity in vivo. To test this, we performed a first-in-human multi-center phase 1 trial (ClinicalTrials.gov NCT01885897) of the IL-15 superagonist complex ALT-803 in patients who relapsed >60 days after allo-HCT...
February 20, 2018: Blood
https://www.readbyqxmd.com/read/29463446/how-to-treat-chronic-myeloid-leukemia-cml-in-older-adults
#19
Marlise R Luskin, Daniel J DeAngelo
Chronic myeloid leukemia (CML), a myeloproliferative neoplasm defined by the t(9;22)(q34;q11) chromosomal translocation, primarily affects older adults. Historically, effective treatment options were not available for older CML patients ineligible for curative allogeneic stem cell transplant, and the disease was therefore usually fatal within several years of diagnosis. The development of tyrosine kinase inhibitors (TKIs) that effectively target the constitutively active mutant tyrosine kinase in CML has dramatically improved outcomes for all patients with CML, including older patients...
February 18, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29459719/mir-142-3p-regulates-autophagy-by-targeting-atg16l1-in-thymic-derived-regulatory-t-cell-ttreg
#20
Chuanyong Zhang, Hongbing Shen, Yunjie Lu, Ji Gao, Shaopeng Zhang, Jian Gu, Hao Lu, Yongxiang Xia, Qin Zhu, Xiaofeng Qian, Feng Zhang, Keli L Hippen, Bruce R Blazar, Ling Lu, Xuehao Wang
Thymic-derived regulatory T cell (tTreg) clinical trials show therapeutic promise in the prevention of acute graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation patients. However, strategies are needed to improve tTreg proliferative ability and survival as a means to improve tTreg therapy and reduce the requirement for producing large numbers of Treg cells for adoptive tTreg transfer. Autophagy is a self-degradative process for cytosolic components, which is involved in cells death, differentiation, lymphocyte homeostasis, and tTreg function...
February 19, 2018: Cell Death & Disease
keyword
keyword
82751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"